Evidence map›Paper›PMID 41294846›Full record

ReviewCells2025

Immune Age, Cardiovascular Disease, and Anti-Viral Immunity.

Kevin-Phu C Le, Fahad Shuja, Jorg J Goronzy, Cornelia M Weyand

Abstract readReview
In one paragraph

Review in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kevin-Phu C LeDepartment of Medicine, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0001-5098-7737
Fahad ShujaDivision of Vascular and Endovascular Surgery, Department of Surgery, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0009-0003-2274-1723
Jorg J GoronzyDepartment of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Cornelia M WeyandDepartment of Medicine, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0003-2230-9802

Funding

The NOTCH Signaling Pathway in Large Vessel VasculitisR01HL117913 · NHLBI · STANFORD UNIVERSITY · PI WEYAND, CORNELIA M. · 2014 to 2025
$5.0M
Oligoclonal T Cell Expansion &Rheumatoid ArthritisR01AR042527 · NIAMS · STANFORD UNIVERSITY · PI WEYAND, CORNELIA M. · 1993 to 2022
$4.8M
MSTP at Mayo Clinic RochesterT32GM145408 · NIGMS · MAYO CLINIC ROCHESTER · PI SCOTT H KAUFMANN, LISA A SCHIMMENTI · 2023 to 2026
$4.7M
microRNA Regulation of T Cell SenescenceR01AI108891 · NIAID · PALO ALTO VETERANS INSTIT FOR RESEARCH · PI GORONZY, JORG J · 2014 to 2023
$4.6M
Telomere Damage Responses and Immune AgingR01AI108906 · NIAID · STANFORD UNIVERSITY · PI WEYAND, CORNELIA M. · 2014 to 2024
$4.0M
Influence of Age on CD4 T Memory CellsR01AG045779 · NIA · PALO ALTO VETERANS INSTIT FOR RESEARCH · PI GORONZY, JORG J · 2013 to 2023
$4.0M
T Cell Immunity in Giant Cell ArteritisR01HL142068 · NHLBI · STANFORD UNIVERSITY · PI Cornelia M. Weyand · 2018 to 2026
$3.3M
Memory T Cell Development and Survival in T Cell Responses of Older IndividualsR01AI129191 · NIAID · PALO ALTO VETERANS INSTIT FOR RESEARCH · PI GORONZY, JORG J · 2017 to 2021
$1.9M
Mechanisms of genetic variants in TH2 autoimmunityR01AI184360 · NIAID · MAYO CLINIC ROCHESTER · PI JORG J GORONZY · 2024 to 2026
$1.8M
Mitochondrial Malfunction in T Cell Aging and Tissue InflammationU01AI179609 · NIAID · MAYO CLINIC ROCHESTER · PI Cornelia M. Weyand · 2024 to 2026
$1.7M
Lipid-Loaded Macrophages in Atherosclerotic Plaque InflammationF30HL177853 · NHLBI · MAYO CLINIC ROCHESTER · PI Kevin-Phu C Le · 2025 to 2026
$100k
NHLBI NIH HHS F30 HL177853NHLBI NIH HHS R01 HL117913NHLBI NIH HHS R01 HL142068NIAID NIH HHS R01 AI108891NIAID NIH HHS R01 AI108906NIAID NIH HHS R01 AI129191NIAID NIH HHS R01 AI184360NIAID NIH HHS U01 AI179609NIAMS NIH HHS R01 AR042527NIA NIH HHS R01 AG045779NIGMS NIH HHS T32 GM145408
6 · The paper itself

Abstract

Cardiovascular morbidity and mortality rise precipitously during the 6th-9th decades of life, identifying aging as a critical risk factor. Simultaneously, older individuals are susceptible to severe viral infection, raising the question whether shared mechanisms exist that predispose to both cardiovascular disease (CVD) and failing anti-viral immunity. The aging process causes steady decline in immune fitness (immune aging), which undermines the ability to generate protective anti-viral immune responses. Paradoxically, the aging immune system supports unopposed inflammatory pathways (inflammaging), which exacerbates tissue inflammation in CVD, specifically atherosclerosis. Here, we review the current evidence of how innate and adaptive immune aging promotes tissue-destructive inflammation in atherosclerosis while failing to fight viral infections. Further, we consider how these two disease processes mutually influence each other. We propose that mounting an effective anti-viral response induces off-target bystander activation and exhausts immune cells, ultimately exacerbating CVD. Additionally, we explore how atherosclerotic CVD impacts innate immunity through epigenetic modification of hematopoietic precursors and metabolically conditioning immune cells, leading to a dysfunctional immune system that accelerates plaque inflammation while simultaneously impairing host defense.

Indexed as

AgingCardiovascular DiseasesVirus DiseasesAdaptive ImmunityAnimalsAtherosclerosisHumansImmunity, InnateInflammationatherosclerosisB cell agingcardiovascular diseaseDNA methylationhematopoietic stem cellimmune checkpointmacrophage agingT cell agingviral infection

Identifiers

PMID41294846
PMCPMC12650980

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.